Floatz logo

Ipilimumab

Penile Squamous Cell Carcinoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Penile Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Institute of Cancer Research, United Kingdom
Phase 3B
Nivolumab
National Cancer Institute (NCI)
Phase 2B
Ifosfamide
Institute of Cancer Research, United Kingdom
Phase 3B
Rigosertib
Traws Pharma, Inc.
Phase 2B
Atezolizumab
National Cancer Institute (NCI)
Phase 2CCC

View all 14 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →